AVITA Medical, Inc. Share Price

Equities

RCEL

US05380C1027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:01:12 01/05/2024 BST 5-day change 1st Jan Change
8.52 USD +1.43% Intraday chart for AVITA Medical, Inc. -1.28% -38.34%

Financials

Sales 2024 * 115M 74.81M 5.99B Sales 2025 * 164M 106M 8.51B Capitalization 334M 216M 17.34B
Net income 2024 * -56M -36.33M -2.91B Net income 2025 * -17M -11.03M -883M EV / Sales 2024 * 2.72 x
Net cash position 2024 * 19.8M 12.84M 1.03B Net cash position 2025 * 1.85M 1.2M 96.34M EV / Sales 2025 * 2.03 x
P/E ratio 2024 *
-6.17 x
P/E ratio 2025 *
-31.2 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.34%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

1 day+1.43%
1 week-1.28%
Current month+0.71%
1 month-45.59%
3 months-51.74%
6 months-13.23%
Current year-38.34%
More quotes
1 week
8.01
Extreme 8.01
8.85
1 month
8.01
Extreme 8.01
15.70
Current year
8.01
Extreme 8.01
18.93
1 year
8.01
Extreme 8.01
21.70
3 years
4.41
Extreme 4.4102
22.49
5 years
4.41
Extreme 4.4102
55.35
10 years
3.75
Extreme 3.75
55.35
More quotes
Date Price Change Volume
01/05/24 8.49 +1.07% 4 764
30/04/24 8.4 -3.67% 145,172
29/04/24 8.72 +2.35% 189,868
26/04/24 8.52 +2.65% 285,980
25/04/24 8.3 -3.15% 251,806

Delayed Quote Nasdaq, May 01, 2024 at 02:46 pm

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.94 AUD
Average target price
39.74 AUD
Spread / Average Target
+207.22%
Consensus